CYTK.NASDAQCytokinetics INC

Form 4: Cytokinetics Executive Fady Ibraham Malik Executes Stock Option and Sells Shares

Sentiment:

SEC Form 4 Filing


EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, exercised stock options and sold shares on August 6th and 7th, 2024.

Summary

  • Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, executed a transaction involving Cytokinetics' common stock.
  • On August 7, 2024, Malik exercised a non-qualified stock option to acquire 5,300 shares at a price of $7.96 per share.
  • On August 6, 2024, Malik sold 2,000 shares at $53.74 and 5,300 shares at $53.70.
  • Following these transactions, Malik directly owns 121,704 shares of Cytokinetics' common stock.
  • Malik also directly owns 47,700 derivative securities in the form of non-qualified stock options.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking to understand management's perspective on the company's stock.

Stakeholder Impact

  • Shareholders may interpret the transactions as a signal of the executive's confidence (or lack thereof) in the company's future performance.
  • The transactions have a minor impact on the overall shareholding structure of the company.

Key Dates

DateDescription
03/26/2015Date exercisable for Non-Qualified Stock Option (Right to Buy)
08/06/2024Date of stock sales
08/07/2024Date of stock option exercise
02/26/2025Expiration date for Non-Qualified Stock Option (Right to Buy)

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.